Welcome to our dedicated page for Globus Med news (Ticker: GMED), a resource for investors and traders seeking the latest updates and insights on Globus Med stock.
Globus Medical reports recurring developments in musculoskeletal technology, including sales and earnings updates for its spine, orthopedic and enabling technology businesses. The company develops medical devices, instruments and computer-assisted systems used in musculoskeletal procedures and sells to hospitals, physicians and surgical centers in the United States and international markets.
Company news also covers US Spine demand, Enabling Technologies customer expansion, product pipeline execution, integration activity following completed NuVasive and Nevro transactions, preliminary sales guidance, earnings conference calls and board composition changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Globus Medical (NYSE: GMED) will announce its Q1 2023 financial results on May 4, 2023, after market close. A teleconference is scheduled for the same day at 4:30 p.m. ET, allowing investors to discuss the results. The conference call will be streamed live via the company's website. Participants can also join via telephone by registering for the event. Globus Medical specializes in musculoskeletal solutions and was founded in 2003. The company emphasizes its dedication to product innovation for surgeon-assisted healing. A recording of the call will be available on the investor page following the event. For further information, details are accessible on the company’s website.
Globus Medical (NYSE: GMED) announced its financial results for Q4 and full year 2022, reporting worldwide net sales of $274.5 million for Q4, a 9.8% increase year-over-year, and $1,022.8 million for the full year, a 6.8% rise. GAAP net income for Q4 soared to $50.1 million, a 231.4% increase from the prior year, while diluted EPS was $0.49. The company achieved non-GAAP diluted EPS of $0.59. Free cash flow for 2022 reached $104.4 million, with no debt reported. Looking ahead, Globus forecasts 2023 net sales of $1.1 billion and non-GAAP diluted EPS of $2.30.